
| Pair Name | RA-V, Doxorubicin | ||
| Phytochemical Name | RA-V (PubChem CID: 13361282 ) | ||
| Anticancer drug Name | Doxorubicin (PubChem CID: 31703 ) | ||
| Structure of Phytochemical |
Download
2D
MOL
3D
MOL
|
||
| Structure of Anticancer Drug |
Download
2D
MOL
3D
MOL
|
||
| Pair Name | RA-V, Doxorubicin | |||
| Disease Info | [ICD-11: 2C77.Z] | Cervical cancer | Investigative | |
| Biological Phenomena | Induction-->Mitochondria-mediated apoptosis | |||
| Gene Regulation | Up-regulation | Expression | CYCS | hsa54205 |
| In Vitro Model | HeLa | Human papillomavirus-related cervical adenocarcinoma | Homo sapiens (Human) | CVCL_0030 |
| In Vivo Model | The HeLa cells (5×10⁶ cells) were transplanted subcutaneously into the 8-week female BALB/c nude mice by using a stereotactic fixation device with mouse adaptor. | |||
| Result | This work represents a versatile strategy for precise combination therapy against resistant tumor with spatiotemporal control, and provides a potential tool for Cyt c-related apoptotic studies. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Sequential Delivery of Cyclopeptide RA-V and Doxorubicin for Combination Therapy on Resistant Tumor and In Situ Monitoring of Cytochrome c Release. Theranostics. 2017 Aug 23;7(15):3781-3793. doi: 10.7150/thno.20892. | Click |